This website is best viewed using the vertical display on your mobile device.

Prof Dr Karim Vermaelen

Karim Vermaelen is Associate Professor, Tumour Immunology Laboratory, Ghent University, Belgium, and Clinical Staff Member, Department of Respiratory Medicine, Ghent University Hospital. Since 2011, he has been Coordinator of Ghent University Hospital Spearhead Research Program on Clinical Immunology, and in 2012 he started the Tumour Immunology Laboratory, an independent research group. In 2016, he co-founded the Immuno-Oncological Network Ghent, an expertise platform connecting and promoting basic, translational and clinical research in cancer immunology.

Professor Vermaelen is Senior Clinical Investigator for the Flanders Fund for Scientific Research and is involved in industry-sponsored clinical trials investigating immunotherapy for lung cancer. His research interests are three-fold: fundamental research into lung tumour–associated dendritic cells; translational research, including development of a novel oncoimmune humanised mouse model of lung cancer; and clinical research into development of a clinical-grade dendritic cell–based vaccine platform. During his career, he has received a number of awards, including the Boehringer Ingelheim Award in Pulmonology, and in 2008 he was awarded a European Respiratory Society Short-Term Research Fellowship. He is a member of the American Association of Cancer Research, the European Academy of Tumor Immunology, the International Association for the Study of Lung Cancer, the European Respiratory Society – Thoracic Oncology Assembly, and the Belgian Society for Pneumology. He has authored several notable articles, which have appeared in journals such as the International Journal of Cancer and Nature Medicine.